CompletedNot Applicable

Studying DNA in Tissue Samples From Caucasian and African-American Cancer Patients Who Received Docetaxel on Clinical Trial CLB-9871

69 participantsStarted 2008-10

Plain-language summary

This research trial studies deoxyribonucleic acid (DNA) in blood samples from Caucasian and African-American cancer patients who received docetaxel on clinical trial CLB-9871. Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors learn more about how docetaxel is used by the body.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

* Registration to CALGB 9871 * Samples present within the CALGB Pathology Coordinating Office that are sufficient to meet study aims

What they're measuring

Incidence of ABBC2 polymorphism (rs12762549) and a SLC01B3 polymorphism (rs11045585) with docetaxel exposure

Timeframe: Up to 2 years

Incidence of SLC01B3 polymorphism (rs11045585)

Timeframe: Up to 2 years

Trial details

NCT IDNCT01015963

SponsorAlliance for Clinical Trials in Oncology

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2013-01

View on ClinicalTrials.gov More Bladder Cancer trials